Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3589 - CNS penetration and Preliminary Efficacy of Sacutizumab Govitecan in Breast Brain Metastasis and Glioblastoma: A Surgical Study

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Andrew Brenner

Citation

Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243

Authors

A.J. Brenner1, J. Floyd2, P. Surapaneni3, V. Kaklamani1, V. Madhusudanan-Kunnuparampil1, S. Tiziani4

Author affiliations

  • 1 Medical Oncology, Mays Cancer Center at UTHSCSA, 78229-3264 - San Antonio/US
  • 2 Neurosurgery, UT Health San Antonio, 78229 - San antonio/US
  • 3 Oncology, UT Health San Antonio, 78229 - San antonio/US
  • 4 Nutrition, UT Austin, Austin/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3589

Background

Sacituzumab govitecan (SG) is an antibody drug conjugate (ADC) that targets Trop-2 for the selective delivery of SN-38 to tumors. SG carries SN-38, a topoisomerase inhibitor active in the nanomolar range for most cells (including TNBC and GBM) and freely cross the blood brain barrier. SN-38 is conjugated to SG by a linker designated CL2A which is sensitive to acidic and conditions. SG was evaluated in a single-arm, multicenter trial with relapsed/refractory metastatic triple negative breast cancer (TNBC) with impressive results including a confirmed objective response rate of 30%, with responses occurring early (median onset of 1.9 months) and being durable (median duration 8.9m). SG has since been granted priority review designation by the FDA, with approval anticipated. Brain metastases is a significant concern in this patient population, but whether this agent is able to target the CNS through the blood brain barrier is unknown. Based upon the characteristics of this specific ADC, including the use of a pH labile linker and a payload with good CNS penetration, it is our specific hypothesis that the SG can achieve intratumoral concentrations of SN-38 sufficient to achieve therapeutic benefit in patients with neoplastic involvement of the brain. We further hypothesize that while total concentration of SN-38 will correlate with expression of trop2, free SN-38 will correlate more strongly with intratumoral hypoxia.

Trial design

Single center, non-randomized, prospective study of SG in subjects with CNS involvement and planned surgical resection. SG is given as single dose at 10mg/kg administered pre-operatively on Day-1. Surgery will be followed by post-operative treatment with sacituzumab govitecan given intravenously with standard dose of 10 mg/kg on day1 and day 8 of 21-day cycle, until disease progression. Approximately 20 patients, 2 cohorts of 10 patients each with GBM and breast brain tumors from TNBC.Tumors will be analyszed for total antibody (hRS7 + hRS7-SN-38), free SN-38, and total SN-38 (free SN-38 + hRS7-SN-38) concentrations in tumor tissue. Correlations will be made to Trop2 expression and hypoxia.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

University of Texas Health San Antonio.

Funding

Mays Cancer Center, Kolitz Endowment.

Disclosure

A.J. Brenner: Research grant / Funding (institution): Immunomedics. V. Kaklamani: Research grant / Funding (institution): Immunomedics. V. Madhusudanan-Kunnuparampil: Research grant / Funding (institution): Immunomedics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.